Immune Checkpoints Articles & Analysis
22 articles found
Alfa Cytology unveils advanced PD-1 inhibitor development service for cancer research. Alfa Cytology, a prominent service provider in the oncology landscape, has recently launched its innovative PD-1 inhibitor development services. This initiative marks a significant advancement in the quest for more effective cancer therapies, focusing on enhancing precision and adaptability in treatment ...
Immuno-oncology is an innovative field that utilizes the body’s immune system to combat cancer. By harnessing the natural capabilities of the immune system, immuno-oncology services are revolutionizing the way we approach cancer treatment, offering novel therapies that are changing the prognosis for many patients. Understanding Immuno-Oncology Immuno-oncology focuses on the interaction ...
As we step into 2024, the global health landscape is increasingly focused on combatting viral infections, which continue to pose significant threats to public health. The COVID-19 pandemic has illuminated the critical need for innovative strategies in antiviral research, and scientists worldwide are embarking on groundbreaking projects to develop more effective therapies, vaccines, and preventive ...
The immune system plays a crucial role in protecting the body from harmful pathogens and foreign invaders. Immune receptors, which are protein molecules expressed on the membrane of immune cells, play a key role in regulating immune responses. These receptors can interact with specific ligands to trigger a cascade of events that lead to the activation or suppression of immune responses. Immune ...
Brain tumors can be broadly categorized into primary and secondary (or metastatic) tumors. Primary tumors originate in the brain1, while secondary tumors spread from other body parts. Treatment options traditionally include surgery, radiation therapy, and chemotherapy. However, these approaches can be invasive and have severe side effects. The battle against brain tumors is being ...
Dr. Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons. The oncology field is rapidly advancing with the development of antibody-drug conjugates (ADCs), offering new hope for ...
ByTempus
What is a Nanobody?Nanobodies are the smallest functional single-domain antibodies known to be able to stably bind to antigens, and have unique structural and functional advantages. The molecular weight of nanobodies is only 12-15 kDa, which retains the antigen binding ability of traditional antibodies. However, nanobodies have higher solubility and stability, and have unique advantages in ...
What is CD73? CD73, also known as ecto-5′-nucleotidase, is a groundbreaking immunoinhibitory protein that assumes a pivotal role in tumor growth and metastasis. Its primary function revolves around converting extracellular ATP into immunosuppressive adenosine, working in tandem with CD39 within normal tissues to curtail excessive immune reactions. However, this mechanism is often hijacked ...
In recent years, PROteolysis TArgeting Chimeras (PROTAC), which utilizes the cell's own degradation mechanisms to eliminate specific disease-related proteins, has emerged as one of the most promising methods. Apart from PROTAC, various targeted protein degradation (TPD) strategies are emerging, involving molecular glue, Autophagy-Targeting Chimera (AUTEC), Autophagosome Tethering Compound ...
Infectious diseases seriously threaten human health, and various infectious diseases may cause millions of severe cases and even death every year. Vaccination has been one of the most effective public health interventions in history, preventing millions of deaths worldwide. However, the success of vaccines relies not only on the antigens they carry but also on additional components known as ...
In the search for innovative and effective ways to target cancer, we are faced with more than just a challenging problem; we are faced with our own cells as opponents. Cancer cells evolve to achieve an optimum of physical fitness, giving them an array of abilities that no cell should possess in a healthy organism. One way to find novel therapies against cancer therefore could imply finding a ...
Cytokines-mediated signaling is a primary way of immune system communication. The common gamma-chain family of cytokines is a set of six cytokines that signal through the common cytokine γ chain receptor (γc/CD132/IL2RG). These cytokines include IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Besides the IL-2RG receptor subunit, the γc family cytokine receptors include IL-2RB ...
A study conducted under the Lung Cancer Master Protocol (Lung-MAP) found that when treated with a combination of ramuzumab (Cyramza) and Keytruda, Patients with advanced NSCLC whose cancer progressed during prior immunotherapy lived significantly longer than when treated with one of the current standard therapies for this cancer. The hazard ratio (80% confidence interval) for overall survival ...
Researchers at The University of Texas MD Anderson Cancer Center have identified a new strategy to reduce immune-related adverse events by targeting immunotherapy with the cytokine interleukin-6 (IL-6). The study, published in Cancer Cell, provides evidence for the concept of combining immune checkpoint blockers and cytokine blockers to selectively inhibit inflammatory autoimmune responses. ...
On March 19, Bristol-Myers Squibb (BMS) announced that its dual immunotherapy combination Opdualag had received accelerated marketing approval from the FDA. Opdualag therapy is a fixed-dose combination of Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) for the treatment of adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma, making LAG-3 the third ...
Background Tumor immunotherapies compose immune checkpoint inhibitors, therapeutic antibodies, tumor vaccines, cellular therapies, and so on. However, each has its own set of issues, such as the fact that CAR-T therapy is an individual therapy that is costly; immune checkpoint inhibitors are highly effective, but only in some patients. The researchers expose us to a radically different way of ...
Pancreatic cancer is a highly malignant tumor of the digestive tract that is difficult to diagnose and treat, and the morbidity and mortality rates have risen dramatically in recent years. Pancreatic cancer is at an advanced stage when diagnosed when cancer cells have spread and are hard to control. The most frequent pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), accounting for ...
The advent of immune checkpoint inhibitors (ICI) has improved the overall survival of patients with a variety of malignancies. However, the problem of drug resistance to ICI therapy remains a major obstacle limiting its clinical application. The development of drug resistance is associated with multiple factors, including the level of PD-L1 expression in tumor cells, the tumor microenvironment, ...
Immunotherapy, in addition to surgery, chemotherapy, and radiotherapy, has now become the fourth pillar of anticancer treatment, with T cell-based immunotherapy being a successful cancer treatment technique. T cells can be separated into two subpopulations based on the expression of T-cell receptors (TCRs). αβ T cells, expressing expressing αβ TCR, recognize peptide antigens, such as those ...
Over time, genetic research have recognized a number of genetic danger variants related to neurodegenerative problems and helped reveal new organic pathways and genes of curiosity. Nevertheless, genetic danger variants generally reside in non-coding areas and should regulate distant genes reasonably than the closest gene, in addition to a gene’s interplay companions in organic networks. ...